Amy House | VP Corporate Development and Communications
Beacon Therapeutics

Amy House is Vice President of Corporate Development and Communications at Beacon Therapeutics, a clinical-stage biotechnology company advancing gene therapies for ocular diseases. She brings over 20 years of experience across healthcare and the life sciences spanning industry, academia, and consulting. Previously, Amy served as Chief of Staff to the Chief Medical Officer at Gyroscope Therapeutic, where she also led integration and transition efforts following its acquisition by Novartis. Earlier in her career, she developed and managed strategic collaborations for faculty with industry partners and investors at Johns Hopkins Technology Ventures. She also advised health care organizations and life sciences companies across all stages of development as a management consultant. Amy leverages her broad experience to bridge scientific innovation, clinical development and commercial strategy, and to foster high performing teams that accelerate innovation and impact. Amy has an MBA from Duke University and a BA in Public Health from Johns Hopkins University.